S&P 500   3,690.77 (+0.66%)
DOW   30,131.88 (+0.54%)
QQQ   305.43 (+0.38%)
AAPL   122.19 (-0.61%)
MSFT   214.19 (-0.02%)
FB   280.32 (-0.54%)
GOOGL   1,824.78 (+0.16%)
AMZN   3,174.63 (-0.38%)
TSLA   594.55 (+0.20%)
NVDA   540.13 (+0.80%)
BABA   267.33 (+0.16%)
CGC   28.99 (+1.26%)
GE   10.72 (+1.13%)
MU   73.39 (+4.99%)
AMD   93.53 (+1.32%)
T   29.52 (+0.99%)
NIO   43.40 (-4.30%)
F   9.39 (+1.95%)
ACB   11.67 (+3.83%)
BA   233.16 (-1.70%)
NFLX   499.14 (+0.33%)
GILD   61.27 (+0.67%)
DIS   153.49 (+0.16%)
S&P 500   3,690.77 (+0.66%)
DOW   30,131.88 (+0.54%)
QQQ   305.43 (+0.38%)
AAPL   122.19 (-0.61%)
MSFT   214.19 (-0.02%)
FB   280.32 (-0.54%)
GOOGL   1,824.78 (+0.16%)
AMZN   3,174.63 (-0.38%)
TSLA   594.55 (+0.20%)
NVDA   540.13 (+0.80%)
BABA   267.33 (+0.16%)
CGC   28.99 (+1.26%)
GE   10.72 (+1.13%)
MU   73.39 (+4.99%)
AMD   93.53 (+1.32%)
T   29.52 (+0.99%)
NIO   43.40 (-4.30%)
F   9.39 (+1.95%)
ACB   11.67 (+3.83%)
BA   233.16 (-1.70%)
NFLX   499.14 (+0.33%)
GILD   61.27 (+0.67%)
DIS   153.49 (+0.16%)
S&P 500   3,690.77 (+0.66%)
DOW   30,131.88 (+0.54%)
QQQ   305.43 (+0.38%)
AAPL   122.19 (-0.61%)
MSFT   214.19 (-0.02%)
FB   280.32 (-0.54%)
GOOGL   1,824.78 (+0.16%)
AMZN   3,174.63 (-0.38%)
TSLA   594.55 (+0.20%)
NVDA   540.13 (+0.80%)
BABA   267.33 (+0.16%)
CGC   28.99 (+1.26%)
GE   10.72 (+1.13%)
MU   73.39 (+4.99%)
AMD   93.53 (+1.32%)
T   29.52 (+0.99%)
NIO   43.40 (-4.30%)
F   9.39 (+1.95%)
ACB   11.67 (+3.83%)
BA   233.16 (-1.70%)
NFLX   499.14 (+0.33%)
GILD   61.27 (+0.67%)
DIS   153.49 (+0.16%)
S&P 500   3,690.77 (+0.66%)
DOW   30,131.88 (+0.54%)
QQQ   305.43 (+0.38%)
AAPL   122.19 (-0.61%)
MSFT   214.19 (-0.02%)
FB   280.32 (-0.54%)
GOOGL   1,824.78 (+0.16%)
AMZN   3,174.63 (-0.38%)
TSLA   594.55 (+0.20%)
NVDA   540.13 (+0.80%)
BABA   267.33 (+0.16%)
CGC   28.99 (+1.26%)
GE   10.72 (+1.13%)
MU   73.39 (+4.99%)
AMD   93.53 (+1.32%)
T   29.52 (+0.99%)
NIO   43.40 (-4.30%)
F   9.39 (+1.95%)
ACB   11.67 (+3.83%)
BA   233.16 (-1.70%)
NFLX   499.14 (+0.33%)
GILD   61.27 (+0.67%)
DIS   153.49 (+0.16%)
Log in
NASDAQ:ADPT

Adaptive Biotechnologies Stock Forecast, Price & News

$47.83
-0.03 (-0.06 %)
(As of 12/4/2020 12:27 PM ET)
Add
Compare
Today's Range
$46.82
Now: $47.83
$47.90
50-Day Range
$45.01
MA: $48.54
$51.93
52-Week Range
$15.19
Now: $47.83
$54.20
Volume8,664 shs
Average Volume1.07 million shs
Market Capitalization$6.54 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.28
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test; and Amgen to develop a therapeutic to prevent or treat COVID-19. It serves the life sciences research, clinical diagnostics, and drug discovery customers. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was founded in 2009 and is headquartered in Seattle, Washington.
Adaptive Biotechnologies logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.42 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADPT
CUSIPN/A
CIKN/A
Phone206-659-0067
Employees453

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$85.07 million
Book Value$5.67 per share

Profitability

Net Income$-68,610,000.00
Net Margins-132.32%

Miscellaneous

Market Cap$6.54 billion
Next Earnings Date2/24/2021 (Estimated)
OptionableNot Optionable
$47.83
-0.03 (-0.06 %)
(As of 12/4/2020 12:27 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ADPT News and Ratings via Email

Sign-up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Adaptive Biotechnologies (NASDAQ:ADPT) Frequently Asked Questions

How has Adaptive Biotechnologies' stock price been impacted by Coronavirus?

Adaptive Biotechnologies' stock was trading at $21.52 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ADPT shares have increased by 122.3% and is now trading at $47.83.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Adaptive Biotechnologies?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptive Biotechnologies in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Adaptive Biotechnologies
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Adaptive Biotechnologies?

Wall Street analysts have given Adaptive Biotechnologies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Adaptive Biotechnologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Adaptive Biotechnologies' next earnings date?

Adaptive Biotechnologies is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Adaptive Biotechnologies
.

How were Adaptive Biotechnologies' earnings last quarter?

Adaptive Biotechnologies Co. (NASDAQ:ADPT) issued its earnings results on Sunday, November, 15th. The company reported ($0.27) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.28) by $0.01. The firm earned $26.30 million during the quarter, compared to analyst estimates of $23.58 million. Adaptive Biotechnologies had a negative return on equity of 20.15% and a negative net margin of 132.32%. The business's quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.11) earnings per share.
View Adaptive Biotechnologies' earnings history
.

What price target have analysts set for ADPT?

6 Wall Street analysts have issued twelve-month price objectives for Adaptive Biotechnologies' stock. Their forecasts range from $46.00 to $63.00. On average, they anticipate Adaptive Biotechnologies' share price to reach $55.80 in the next twelve months. This suggests a possible upside of 16.7% from the stock's current price.
View analysts' price targets for Adaptive Biotechnologies
.

Are investors shorting Adaptive Biotechnologies?

Adaptive Biotechnologies saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 7,170,000 shares, an increase of 49.7% from the October 31st total of 4,790,000 shares. Based on an average daily trading volume, of 864,700 shares, the short-interest ratio is currently 8.3 days.
View Adaptive Biotechnologies' Short Interest
.

Who are some of Adaptive Biotechnologies' key competitors?

What other stocks do shareholders of Adaptive Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adaptive Biotechnologies investors own include NVIDIA (NVDA), Alibaba Group (BABA), QUALCOMM (QCOM), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), CrowdStrike (CRWD), The Home Depot (HD), Inovio Pharmaceuticals (INO), PayPal (PYPL) and Tesla (TSLA).

Who are Adaptive Biotechnologies' key executives?

Adaptive Biotechnologies' management team includes the following people:
  • Mr. Chad M. Robins M.B.A., M.B.A, Co-Founder, CEO & Chairman (Age 46, Pay $878.5k)
  • Dr. Harlan S. Robins Ph.D., Co-Founder & Chief Scientific Officer (Age 47, Pay $669.35k)
  • Dr. Lance Baldo, Chief Medical Officer (Age 47, Pay $548.99k)
  • Ms. Julie Rubinstein, Pres (Age 48)
  • Mr. Christopher Carlson Ph.D., Founder
  • Mr. Chad M. Cohen C.P.A., Chief Financial Officer (Age 45)
  • Ms. Nancy L. Hill, Exec. VP of Operations & Program Management (Age 56)
  • Dr. Mark Adams, Chief Technical Officer (Age 53)
  • Ms. Stacy L. Taylor, Sr. VP & Gen. Counsel (Age 60)
  • Mr. Francis T. Lo, Chief People Officer (Age 39)

When did Adaptive Biotechnologies IPO?

(ADPT) raised $200 million in an initial public offering on Thursday, June 27th 2019. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers.

What is Adaptive Biotechnologies' stock symbol?

Adaptive Biotechnologies trades on the NASDAQ under the ticker symbol "ADPT."

Who are Adaptive Biotechnologies' major shareholders?

Adaptive Biotechnologies' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.91%), Massachusetts Financial Services Co. MA (2.17%), Neuberger Berman Group LLC (1.36%), JPMorgan Chase & Co. (1.04%), Wells Fargo & Company MN (0.81%) and State Street Corp (0.68%). Company insiders that own Adaptive Biotechnologies stock include Andris A Zoltners, Chad M Cohen, Chad M Robins, Charles Sang, David E Goel, Eric Dobmeier, Francis Lo, Global Investors Lp Viking, Harlan S Robins, Julie Rubinstein, Lance Baldo, Michelle Renee Griffin, Nancy Louise Hill, Robert Hershberg, Sharon Benzeno, Stacy L Taylor, Susan Bobulsky and Viking Global Performance Llc.
View institutional ownership trends for Adaptive Biotechnologies
.

Which major investors are selling Adaptive Biotechnologies stock?

ADPT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Peregrine Capital Management LLC, Platinum Investment Management Ltd., Victory Capital Management Inc., CAPROCK Group Inc., Westover Capital Advisors LLC, New York State Common Retirement Fund, and Crewe Advisors LLC. Company insiders that have sold Adaptive Biotechnologies company stock in the last year include Andris A Zoltners, Chad M Cohen, Chad M Robins, Charles Sang, David E Goel, Eric Dobmeier, Francis Lo, Global Investors Lp Viking, Harlan S Robins, Julie Rubinstein, Lance Baldo, Michelle Renee Griffin, Nancy Louise Hill, Robert Hershberg, Sharon Benzeno, Stacy L Taylor, Susan Bobulsky, and Viking Global Performance Llc.
View insider buying and selling activity for Adaptive Biotechnologies
.

Which major investors are buying Adaptive Biotechnologies stock?

ADPT stock was bought by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Summit Partners Public Asset Management LLC, ARK Investment Management LLC, JPMorgan Chase & Co., First Trust Advisors LP, Lord Abbett & CO. LLC, Charles Schwab Investment Management Inc., and Kornitzer Capital Management Inc. KS. Company insiders that have bought Adaptive Biotechnologies stock in the last two years include Chad M Cohen, Nancy Louise Hill, and Viking Global Performance Llc.
View insider buying and selling activity for Adaptive Biotechnologies
.

How do I buy shares of Adaptive Biotechnologies?

Shares of ADPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Adaptive Biotechnologies' stock price today?

One share of ADPT stock can currently be purchased for approximately $47.83.

How big of a company is Adaptive Biotechnologies?

Adaptive Biotechnologies has a market capitalization of $6.54 billion and generates $85.07 million in revenue each year. The company earns $-68,610,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Adaptive Biotechnologies employs 453 workers across the globe.

What is Adaptive Biotechnologies' official website?

The official website for Adaptive Biotechnologies is www.constructionpartners.net.

How can I contact Adaptive Biotechnologies?

Adaptive Biotechnologies' mailing address is 1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE WA, 98102. The company can be reached via phone at 206-659-0067 or via email at [email protected]

This page was last updated on 12/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.